Navigation Links
Experts discuss ways to embed patient voices and values in clinical research
Date:4/30/2013

Rochester, MN, April 30, 2013 There is worldwide concern in the biomedical research community that enrollment in clinical trials is lagging, putting clinical research and consequent benefits to society in jeopardy. Experts explore ways to embed patient voices and values in clinical research in the current issue of Mayo Clinic Proceedings.

Clinical trials of new drugs, devices, or procedures require the active participation of human volunteers. Mark A. Yarborough, PhD, of the Bioethics Program, University of California Davis, calls for greater transparency about the social value of research in recruiting patients to participate in clinical trials, as part of the initial informed consent process.

"Not all clinical research is equal," Dr. Yarborough says, comparing research into the use of stem cells to improve the life of Huntington's disease patients with "me too" drug studies that are competing with existing and effective (and often cheaper) medicines to treat conditions such as hypertension. "Clinical research has produced a lot of good, life-improving and life-saving drugs that have really improved the lot of patients. But we need to remain mindful that some trials are more deserving of public trust than others." He proposes the incorporation of a clear declaration in informed consent forms that states whether a trial is investigating a way to potentially improve current medical care and explains why it does or does not have the potential to do so.

"We owe the public honest disclosure about why any given trial is being conducted so that they understand the extent to which a trial, if completed, could promote the common good," Dr. Yarborough explains. "The informed consent process is one way to provide this disclosure to prospective research participants."

Yarborough acknowledges that there may be critics but, he continues, "One possible good outcome is just to have discussion about transparency about the research setting. I hope a consensus will emerge from this conversation that increased transparency will help to build the public's trust."

In the same issue, investigators at the Cleveland Clinic and McMaster University report on a prospective observational trial to explore the effect of the timing of obtaining consent. They monitored the timing of seeking informed consent for a moderate- to high-risk trial of clonidine and aspirin in patients undergoing non-cardiac surgery and found that, contrary to expectations, patients did not have increased anxiety or decreased understanding if they are asked on the same day as the surgery is due to take place.

"This is the first study, to our knowledge, to specifically compare the impact of consenting on the day of surgery with consenting before that time on patient comprehension," observes lead investigator Daniel I. Sessler, MD, of the Department of Outcomes Research, Cleveland Clinic. "From a practical perspective, consenting before the day of surgery appears preferable, but proposing moderate- to high-risk research on the day of surgery itself does not compromise essential elements of the consent process."

In an accompanying Editorial, Barbara A. Koenig, PhD, of the Institute for Health & Aging, University of California, San Francisco, notes that both articles focus on just a single component of human research protection: the informed consent process. "We must reform a system that valorizes the informed consent process to the exclusion of other elements of human research participant protection," says Dr. Koenig.

"I applaud efforts to conduct empirical research interrogating standard informed consent practices and we need more well-designed studies," Koenig comments, referring to the study by Sessler and colleagues. "However, current efforts to reform the conduct of human research rest too heavily on revising the informed consent process and place too much emphasis on disclosure of risk or potential researcher conflict of interest to the human research participant, to the relative exclusion of other equally important or potentially more important components of the research approval process."

Koenig also questions whether explaining the social value of a clinical trial to research participants is the answer. "Although I share Yarborough's desire to make certain that the social utility of research is highlighted ... his disclosure-based reform assumes that individual patients, confronted by information and data, will 'just say no' to research that lacks social value, in the same way they might seek to minimize personal risk," she says.

Koenig believes that a renewed focus on promoting and enabling authentic ethical reflection as well as a new pathway for embedding patient values and voices into the practice of research is needed. "We cannot simply ask individual patients, unaided, to weigh risk levels and evaluate projects by themselves."


'/>"/>

Contact: Rachael Zaleski
mcpmedia@elsevier.com
215-239-3658
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Experts Offer Advice After Yankee Pitchers Trampoline Injury
2. NYU Langone experts present research, clinical advances at neurosurgeons meeting
3. Red Tide Likely in New England This Season, Experts Warn
4. No Proof That Gum Disease Causes Heart Disease, Experts Say
5. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
6. Glaucoma Need Not Steal Sight, Experts Say
7. Healthy Behaviors Extend Life After Cancer, Experts Say
8. Routine Kidney Disease Screening Not Worthwhile, Experts Say
9. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
10. Aim Skin Cancer Warnings at the Young, Too, Experts Say
11. Experts call for clinical trials to test non-skeletal benefits of vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton School’s ... mid-market executives as a kick-off to the fifth annual CEO Connection Mid-Market Convention. ... the University of Pennsylvania campus, followed by the two-day convention, which will target ...
(Date:6/28/2017)... ... 2017 , ... Schneider Insurance and Financial, a Yellowstone County ... Montana, is announcing a focused charity effort to gather regional support for the ... Zoo Montana provide students with current knowledge on the characteristics and behaviors of ...
(Date:6/27/2017)... ... 2017 , ... Excel Medical, the leader in Next-Generation Medical ... Executive Vice President, Sales and Marketing. Finnegan is a widely known industry leader ... leadership. He has received industry recognition for innovations and new approaches to sales ...
(Date:6/27/2017)... Orlando, FL (PRWEB) , ... June 27, 2017 ... ... the leading payment solution for many of the health care industry’s hospitals and ... its new patient financing portal for select customers. Parasail Health is a San ...
(Date:6/27/2017)... California (PRWEB) , ... June 27, 2017 , ... A ... has been projected to reach a staggering $6.81 billion by the year 2024 according ... rising at a faster rate than those made from titanium. Los Angeles area clinic ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: